Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating long-acting cabotegravir plus long-acting rilpivirine versus Biktarvy in virologically suppressed HIV-1 patients completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)
• CAB-LA + RPV-LA (cabotegravir long-acting + rilpivirine long-acting)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2023-09-13